Oncologists at Huaxi Hospital in China’s eastern Sichuan province are preparing to start what appears to be the world’s first human clinical trial using the gene editing technology CRISPR-Cas9, to treat patients with advanced non-small cell lung cancer.
Led by Lu You, the head of the hospital’s lung cancer division, the study has obtained ethics committee clearance and...







